ono-4685
mAbexperimentalMulti-specific
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04079062)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06547528 | Phase 1 | Oct 1, 2023 | Ono Pharmaceuticals |
| NCT05332704 | Phase 1 | Mar 25, 2022 | Ono Pharmaceuticals |
| NCT05079282 | Phase 1 | Nov 30, 2021 | Ono Pharmaceuticals |
| NCT04079062 | Phase 1 | Sep 30, 2019 | Ono Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ono Pharmaceuticals | For profit | 4 | 4 | 1 | 2019 |
1 organizations
Page 1 / 1